Aktienanalyse zu Edap Tms SA (FOCL)FOCLEdap Tms SA

Edap Tms SA is a France-based company that develops, manufactures, promotes and distributes minimally invasive medical devices for urology based upon ultrasound technology. The Company's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. It specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. It also operates worldwide via a network of corporate offices, subsidiaries and distribution partners It operates in the Healthcare sector.

Edap Tms SA (FOCL) appears to be a good buy right now, trading at $4.34 with a strong RSI of 62.29 indicating bullish momentum. The company's gross margin has improved significantly to 55.58%, up from 42.52% in the previous year, showcasing operational efficiency. Additionally, analysts have set a price target of $15 from Mizuho, suggesting a potential upside of over 245% from the current price. However, the main risk is the negative earnings per share forecast of -0.18 for the next earnings report, which could impact investor sentiment.